Capricor Therapeutics, Inc. Aktie News

The Phase 3 trial met its primary and secondary endpoints. Management anticipates approval in 2026, with highly lucrative milestone payments expected to follow in the years to come.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval ...

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares...

Capricor stock skyrocketed to an eight-year high Wednesday on positive results for its Duchenne muscular dystrophy treatment.

Capricor Therapeutics Inc (NASDAQ:CAPR) is one of the best stocks on Wall Street today, up 263% to trade at $23.09, after the biotech company's cell therapy for a heart condition related to Duchenne's muscular dystrophy met the ‌main goal of a late-stage study.

Capricor Therapeutics said on Wednesday its cell therapy for a heart condition related to a rare muscular disorder met the main goal of a late-stage study, months after U.S. regulators rejected its initial approval bid.